OBJECTIVE To evaluate the incremental increase in new onset diabetes from higher potency statins compared with lower potency statins when used for secondary prevention. DESIGN Eight population based cohort studies and a meta-analysis. SETTING Six Canadian provinces and two international databases from the UK and US. PARTICIPANTS 136,966 patients aged ≥ 40 years newly treated with statins ...

BACKGROUND It is a controversy whether statins therapy could be beneficial for the occurrence of atrial fibrillation (AF) in acute coronary syndrome (ACS). To clarify this problem, we performed a meta-analysis with the currently published literatures. METHODS The electronic databases were searched to obtain relevant trials which met the inclusion criteria through October 2011. Two authors ind...

The disabling pathophysiologic effects of lipid and neuroprotective effects of statins have recently been demonstrated for acute spinal cord injuries in animal models. This large scale population-based study aimed to investigate the effect hyperlipidemia and the use of statins in patients with lumbar spine injury. The National Health Insurance Research Database of Taiwan was used to identify pa...

BACKGROUND AND AIM Statins are HMG-CoA reductase inhibitors within the framework of cholesterol biosynthesis and used to lower the low-density lipoprotein (LDL). There are other aspects of statins can deploy a protective effect, even without the LDL's lowering. The aim of this study is to investigate the effects of different type of statins on proliferative and migrative behaviors of Hepatocyte...

Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia. Recently, they are reported to have beneficial effects on certain cancers. In this study, we show that statins inhibited the histone deacetylase (HDAC) activity and increased the accumulation of acetylated histone-H3 and the expression of p21 in human cancer cells. Computational...

Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statin therapy demonstrate an improvement in cardiovascular end points and coronary stenosis. However, an improvement in cardiovascular end points and coronary stenosis is incompletely explained by the baseline or treated LDL cholesterol level. The beneficial effects of statins on clinical events may invo...

BACKGROUND & AIMS HMG-CoA-reductase-inhibitors (statins) have been shown to interfere with HCV replication in vitro. We investigated the mechanism, requirements and contribution of heme oxygenase-1(HO-1)-induction by statins to interference with HCV replication. METHODS HO-1-induction by fluva-, simva-, rosuva-, atorva- or pravastatin was correlated to HCV replication, using non-infectious re...

Statins are the cornerstone of dyslipidemia management, lowering lowdensity lipoprotein (LDL) cholesterol levels and substantially reducing the risk for cardiovascular disease (CVD). However, many patients on statins have CVD despite reductions in LDL cholesterol. Furthermore, the cooccurrence of dyslipidemia, type 2 diabetes, and hypertension is common. A considerable body of evidence demonstr...

OBJECTIVE To evaluate perioperative statin treatment, to explore the rapidly increasing body of literature on the pleiotropic effects of statins, and to suggest a rational strategy of perioperative risk reduction. SUMMARY OF BACKGROUND DATA Vascular, cerebrovascular, and cardiovascular complications are all too common in surgery. Although treatment with beta-blockers is a well-established str...

BACKGROUND The effects of lipophilic statins in heart failure (HF) were controversial. The goal of the present study was to systematically review all randomised controlled trials evaluating the effects of lipophilic statins in patients with HF. METHODS We performed a comprehensive literature search to identify eligible trials that prospectively randomised patients with HF to lipophilic statin...